Publications by authors named "Prerna Lakhwani"

High-grade endometrial carcinomas are a heterogeneous group of clinically aggressive tumours. They include FIGO grade 3 endometrioid adenocarcinoma, uterine papillary serous carcinoma (UPSC), clear cell carcinoma, undifferentiated carcinoma and carcinosarcomas or malignant mixed Mullerian tumour (MMMT). The aim of this study is to look at clinicopathological features and survival outcomes of high-grade endometrial cancers of the uterus in our centre.

View Article and Find Full Text PDF

The objective of this study was to study the risk factors, management protocols, and the outcome of vulvar cancer cases over a period of 2 years in a tertiary care hospital. This is a case series of early-stage vulvar cancer in the Department of Surgical Oncology in BL Kapur Superspeciality Hospital from Jan 2016 to date. Five patients with histologically proven diagnosis of early-stage vulvar cancer were included.

View Article and Find Full Text PDF

Lymphadenectomy is considered an integral part of comprehensive surgical staging of endometrial cancer but debate on the value of lymphadenectomy continues in early-stage endometrial cancer. The aim of our study was to determine the number of node positive patients in clinically early-stage low-grade (G1-G2) endometrioid endometrial cancer. We retro-prospectively analyzed the medical records of 155 women with endometrial pathology coming to the BLK cancer center between January 2015 and December 2017 and studied 60 patients of FIGO grade 1-2 endometrioid endometrial cancer confined to the uterus to determine the nodal positivity.

View Article and Find Full Text PDF

Borderline ovarian tumors (BOTs) are a heterogeneous group of non-invasive epithelial ovarian tumors that occur at a younger age, present in early stage, frequently associated with infertility but are easily curable. Although they may have symptomatic long-term recurrences, they have an excellent prognosis in spite of peritoneal spread. Among the epithelial tumors of the ovary, BOTs fall in the spectrum lying between cystadenomas (benign) and cystadenocarcinomas (malignant).

View Article and Find Full Text PDF